ReviewFrontiers in bioengineering and biotechnology2025
Methodological landscape in the field of integration site identification of retroviruses and retroviral vectors.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8BMC medicine · 2026Article
- Gene therapy for liver diseases: methods, challenges and opportunities.Journal of nanobiotechnology · 2026Review
- Beyond CRISPR: next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication.Cancer cell international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detailed mapping of viral vector integration sites, including retroviral and particularly lentiviral vectors, is critical for assessing their safety in preclinical and clinical studies. Although integration into the host genome follows certain virus-specific patterns, it remains a stochastic event and can cause insertional mutagenesis with diverse consequences, such as oncogene activation. In this review, we trace the evolution of ISA methods applied to retroviruses and derived vectors, from early labor-intensive approaches with limited coverage-such as combined strategies involving restriction analysis, Southern blotting, and subcloning-to modern high-throughput strategies. We discuss key methodologies that shaped the field, including inverse PCR (iPCR), ligation-mediated PCR (LM-PCR), and linear amplification-mediated PCR (LAM-PCR), highlighting their contributions to more comprehensive and unbiased mapping, along with limitations associated with systematic errors stemming from dependence on restriction endonuclease digestion and amplification biases. We also examine recent approaches designed to overcome these limitations, independent of PCR and restriction analysis, which enable a more accurate and undistorted representation of retroviral vector integration profiles. Despite the emergence of new techniques, classical methods-particularly LAM-PCR and its modifications, such as nrLAM-PCR-remain widely used and continue to serve as the standard in many commercial platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.